SS Innovations Announces \$18.6 Million Private Placement to Accelerate Global Growth

Key Highlights

• SS Innovations International, Inc. (Nasdaq: SSII) has completed a significant private placement, raising approximately \$18.6 million in gross proceeds to fund its growth initiatives.
• The financing was led by Company insiders, including directors and executive officers, underscoring their confidence in the company’s future.
• The net proceeds will be used for working capital, general corporate purposes, and to support global expansion efforts, including entry into the United States and European Union markets.
• SS Innovations anticipates a mid-2026 review completion by the U.S. FDA for its flagship SSi Mantra surgical robotic system’s 510(k) premarket notification, and is on track for a CE Mark certification in the European Union within the same year.

Details of the Private Placement

• Total shares sold: 5,774,839 shares of common stock.
• Insider participation:
  • 1,300,006 shares sold at an average of \$4.00 per share (totaling around \$5.2 million) to:
    • Dr. Sudhir Srivastava (Chairman & CEO) — \$2.0 million
    • Dr. Frederic H. Moll (Vice-Chairman) — \$2.0 million
    • Tim Adams (Director) — \$1.197 million
• Institutional and external investors:
  • 4,474,833 shares at \$3.00 per share (totaling approximately \$13.4 million), led by Manipal Global Health Services, an existing major shareholder, and new investors.
• Placement fee: For a \$2.5 million investment by a non-affiliate investor, a FINRA member firm will receive a \$175,000 cash commission and five-year warrants to purchase 41,667 shares at \$3.45 per share.

Strategic Significance for Shareholders

• Insider Confidence: The direct involvement and financial commitment from top executives and directors signals strong insider confidence in SS Innovations’ business prospects and growth trajectory.
• Expansion Plans: The capital raise is set to accelerate the company’s expansion in India and other global markets, while also supporting regulatory efforts to enter the lucrative U.S. and EU markets.
• Regulatory Catalysts: The company expects two major regulatory milestones in 2026:
  • FDA completion of the 510(k) review for the SSi Mantra surgical robotic system (mid-2026)
  • CE Mark certification in the European Union (potentially also in 2026)

  Achievement of these milestones could significantly boost the company’s market opportunities and valuation.

• Product Leadership: The SSi Mantra system is already clinically validated in India, with use in over 100 types of surgical procedures. It features advanced technology, including multi-arm modularity, ergonomic surgeon command centers, 3D 4K visualization, and compatibility with over 40 types of endo-surgical instruments across multiple specialties, including cardiac surgery.
• Share Registration Status: The securities issued in this private placement have not been registered under the Securities Act of 1933 and cannot be offered or sold in the United States without registration or a valid exemption. This is standard for private placements but is important to note for liquidity and trading considerations.

Management Commentary

“The net proceeds from this financing will advance our growth initiatives in India and other existing global markets, while supporting our preparation for entry into the United States and European Union markets. We anticipate that the U.S. Food and Drug Administration will complete its review of our 510(k) premarket notification for our SSi Mantra surgical robotic system by mid-2026. We also continue along the pathway towards a European Union CE Mark certification for the SSi Mantra, which we believe we can also obtain in 2026.”

Dr. Srivastava also emphasized the significance of insider participation, stating it reflects strong internal confidence and commitment to democratizing access to world-class surgical robotic care.

About SS Innovations

SS Innovations International, Inc. develops proprietary surgical robotic technologies with a mission to make robotic surgery affordable and accessible worldwide. Its product suite includes the SSi Mantra surgical robotic system and SSi Mudra surgical instruments, covering a range of robotic procedures including cardiac surgery. The company is headquartered in the U.S. with significant operations in India, and is poised for global expansion.

About the SSi Mantra System

The SSi Mantra is a user-friendly, modular, multi-arm system boasting advanced features such as an ergonomic command center, 3D 4K surgeon and team views, real-time imaging, and support for 40+ types of surgical instruments. It has been clinically validated in India in more than 100 types of procedures, demonstrating its versatility and effectiveness.

Investor and Media Contacts

• Kalle Ahl, CFA, The Equity Group — [email protected], (303) 953-9878
• Devin Sullivan, Managing Director, The Equity Group — [email protected], (212) 836-9608
• Kate Barrette, RooneyPartners LLC — [email protected], (212) 223-0561

Potential Impact on Share Price

This capital raise is a potentially significant share price catalyst for SS Innovations International, Inc. The direct participation of insiders and the involvement of major strategic investors, combined with the company’s clear path to FDA and CE Mark approvals, could boost investor confidence, enhance the company’s liquidity and growth prospects, and drive valuation re-rating in the months ahead. Investors should closely monitor regulatory developments and the company’s progress toward commercialization in key markets.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a qualified financial adviser before making investment decisions. Forward-looking statements contained herein are subject to risks and uncertainties, including but not limited to regulatory approvals, market adoption, and the company’s ability to execute its growth strategy.

View SS Innovations International, Inc. Historical chart here